Categories
Connect with us on LinkedIn
From Hype to Health: What Sword Health Got Right About Evidence
Sword Health didn’t follow the typical digital health playbook. Instead of rushing to market, they invested early in...
The New Standard in Participant-Centric Trials: What Castor’s 2025 Updates Reveal About the Future of Clinical Research
Explore how Castor’s 2025 updates reduce site burden and boost compliance through scalable, flexible DTP workflows.
Building Biotech: From Science to Scale – Strategic Lessons from the Frontline
Hard truths on scaling biotech: data isn’t enough, CEOs matter, and funding follows story—not science.
Do Patients Really Understand Clinical Trials?
Poor comprehension of informed consent disrupts trials. Here’s how to fix it—with data, tech, and actual patient understanding.
Building a Safer, Smarter Future: A Tiered Approach to AI in Life Sciences
Adopt AI in clinical research with confidence using a risk-based framework that ensures privacy, security, and regulatory alignment.
Why a Life Sciences Museum Matters—And What It Can Teach Us About the Future of Medicine
What a Museum of Medicine can teach us about trials, trust, and how the public sees (or doesn’t...
The Catch-22 of eConsent: The Missed Opportunity for Improved Clinical Trials
It’s time to move beyond digital PDFs. Discover how real eConsent can transform trials, reduce dropout, and respect...
Build vs. Buy vs. Partner in Life Sciences: Making the Right Call
How do you decide between building, buying, or partnering? Learn key decision factors and red flags to avoid...
Do CROs Need to Reinvent Themselves in 2025? A Deep Dive with Greg Licholai and Derk Arts
High R&D costs aren’t due to a lack of innovation but inefficiencies in trials. Here’s how we can...
Clinical Trials Aren’t Just About Patients (and That’s Okay)
This article explores the debate between patient-centricity and protocol-centricity in clinical trials, featuring insights from Derk Arts (Castor)...
Strategies to Minimize Participant and Healthcare Provider Burden in Clinical Trials
This article examines strategies to reduce participant and provider burden in clinical trials while ensuring high-quality data collection....
What do we measure with PROs in head and neck cancer? Pain, QoL, adverse events and more
Patient-Reported Outcomes (PROs) are essential in head and neck cancer research, offering insights into symptoms, quality of life,...
A New Perspective on Clinical Research: Accessibility and Innovation
Joost Rigter’s inspiring journey highlights the importance of accessibility in clinical research. From AI-driven tools to simplified communication,...
Local Labs in the EDC: Streamlining Safety and Efficacy Insights
Local labs are a vital part of clinical trials, offering fast, cost-effective insights into safety and efficacy. But...
Beyond Compliance: How Quality Culture Drives Clinical Trial Excellence
Moving beyond compliance, quality culture drives clinical trial innovation through automated processes and measurable results.
eCOA Evolution: Have We Overcomplicated What Used to Work?
A blueprint for engineering elegant eCOA solutions that make complex trials feel simple.
Waiver of Consent vs Waiver of Written Consent
One is very common, the other is rarely granted. Learn the key differences between waiver of consent &...
Unlocking FDA’s Vision for PRO Collection in RWE: Timing, Methods, and Insights
Discover FDA's guidance on collecting PROs for Real-World Evidence (RWE), focusing on timing, methods, and improving data quality.
Connect with us on LinkedIn
